Use Caution/Monitor. Use Caution/Monitor. Additive vasospasm; risk of hypertension. Risk of acute hypertensive episode. iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Monitor BP. Other (see comment). prescription products. Use Caution/Monitor. Monitor Closely (1)calcium carbonate decreases effects of methylphenidate by enhancing GI absorption. Potential for additive CNS stimulation. Potential for additive CNS stimulation. pirbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. guarana increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of perindopril by pharmacodynamic antagonism. Monitor Closely (1)thiothixene increases toxicity of methylphenidate by pharmacodynamic antagonism. Contraindicated. Use Caution/Monitor. Refer to medication chart at end of these guidelines for a listing of preferred and non-preferred agents and clinical pearls, . Potential for additive CNS stimulation. Contraindicated. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Avoid or Use Alternate Drug. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)salmeterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Use Caution/Monitor. Monitor BP. Modify Therapy/Monitor Closely. Risk of acute hypertensive episode. Monitor BP. Modify Therapy/Monitor Closely. only.trifluoperazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Methylphenidate may diminish antihypertensive effects. This drug is available at a higher level co-pay. Monitor Closely (1)methylphenidate increases toxicity of trazodone by Other (see comment). Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Applies only to oral form of both agents. Either increases effects of the other by pharmacodynamic synergism. Potential for additive CNS stimulation. Other (see comment). Potential for additive CNS stimulation. Monitor BP. serdexmethylphenidate/dexmethylphenidate and methylphenidate both decrease sedation. Either increases toxicity of the other by Other (see comment). Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Use Caution/Monitor. Modify Therapy/Monitor Closely. Minor/Significance Unknown. Use Caution/Monitor. Concerta is long-acting Ritalin (methylphenidate). Avoid or Use Alternate Drug. Interaction more likely in certain predisposed pts. . Monitor Closely (1)methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. provider for the most current information. Risk of acute hypertensive episode. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)chlorpromazine, methylphenidate. Monitor Closely (1)hydrocodone, methylphenidate. Use Caution/Monitor. Potential for additive CNS stimulation. serdexmethylphenidate/dexmethylphenidate and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Comment: Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Monitor BP. Applies only to oral form of both agents. Applies only to oral form of both agents. Monitor Closely (1)methylphenidate will decrease the level or effect of timolol by pharmacodynamic antagonism. Monitor BP. Ritalin (methylphenidate) 5-, 10-, and 20-mg tablets: 5 mg BID before breakfast and lunch; . Use Caution/Monitor. Modify Therapy/Monitor Closely. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Table 3. CNS stimulant should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure. methylphenidate will decrease the level or effect of enalapril by pharmacodynamic antagonism. Use Caution/Monitor. Mechanism: unknown. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. only. Monitor BP. Use Caution/Monitor. methylphenidate, epinephrine inhaled. Use Caution/Monitor. Other (see comment). Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Amifampridine. Monitor Closely (1)iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor BP. Use Caution/Monitor. Contraindicated. metaproterenol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. only.perphenazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Applies only to oral form of both agents. cabergoline, methylphenidate. Risk of acute hypertensive episode. Monitor Closely (1)green tea, methylphenidate. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Risk of acute hypertensive episode. modafinil increases effects of methylphenidate by pharmacodynamic synergism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Minor (1)yerba mate increases effects of methylphenidate by pharmacodynamic synergism. Sympathomimetics can antagonize the activity of some antihypertensive agents. Other (see comment). Contraindicated. Modify Therapy/Monitor Closely. Use Caution/Monitor. trifluoperazine, methylphenidate. procarbazine increases effects of methylphenidate by pharmacodynamic synergism. Methylphenidate may diminish antihypertensive effects. methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. Contraindicated. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)lansoprazole decreases effects of methylphenidate by enhancing GI absorption. Methylphenidate may diminish antihypertensive effects. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. These cannot be substituted on a milligram-per-milligram basis. Methylphenidate may diminish antihypertensive effects. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. Use Caution/Monitor. Monitor BP. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Other (see comment). Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Contraindicated. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. dopexamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Comment: Potential for additive CNS effects. Use Caution/Monitor. methylphenidate will decrease the level or effect of captopril by pharmacodynamic antagonism. Trial of ADHD Medication with Fast Onset of Action, Entire Active Day Efficacy Initiated Use Caution/Monitor. Interaction more likely in certain predisposed pts. only. Use Caution/Monitor. Use Caution/Monitor. Potential for additive CNS stimulation. Please confirm that you would like to log out of Medscape. Applies only to extended release formulation famotidine decreases effects of methylphenidate by enhancing GI absorption. Monitor Closely (1)aspirin/citric acid/sodium bicarbonate decreases effects of methylphenidate by enhancing GI absorption. Other (see comment). Methylphenidate may diminish antihypertensive effects. Risk of acute hypertensive episode. Monitor Closely (1)pirbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Applies only to oral form of both agents. Use Caution/Monitor. fluphenazine, methylphenidate. Use Caution/Monitor. Monitor Closely (1)dopexamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Modify Therapy/Monitor Closely. Monitor Closely (1)dexfenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)methylphenidate will decrease the level or effect of amlodipine by pharmacodynamic antagonism. Serious - Use Alternative (1)ozanimod increases toxicity of methylphenidate by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Additive vasospasm; risk of hypertension. Risk of acute hypertensive episode. Caffeine should be avoided or used cautiously. Methylphenidate may diminish antihypertensive effects. Monitor BP. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. only. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)levodopa, methylphenidate. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Avoid or Use Alternate Drug. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Interaction more likely in certain predisposed pts. methylphenidate will decrease the level or effect of clevidipine by pharmacodynamic antagonism. You are being redirected to haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. dopamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of benazepril by pharmacodynamic antagonism. chlorpromazine, methylphenidate. Minor (1)guarana increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)methylphenidate will decrease the level or effect of losartan by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor. Aptensio XR. terbutaline and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. dihydroergotamine, methylphenidate. Use Caution/Monitor. Use Caution/Monitor. Risk of acute hypertensive episode. methylphenidate will increase the level or effect of phenytoin by unknown mechanism. Monitor BP. Interaction more likely in certain predisposed pts. Use Caution/Monitor. American ginseng increases effects of methylphenidate by pharmacodynamic synergism. Desflurane. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Check specific recommendations for drugs that exhibit pH-dependent solubility that may affect their systemic exposure and efficacy. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Contraindicated. Avoid or Use Alternate Drug. Use Caution/Monitor. Monitor Closely (1)haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. This means that you only need to take. Use Caution/Monitor. Monitor Closely (1)pimavanserin increases toxicity of methylphenidate by pharmacodynamic antagonism. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Modify Therapy/Monitor Closely. 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg. methylphenidate will decrease the level or effect of valsartan by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Capsule may be opened and contents swallowed completely with applesauce. Monitor BP. Other (see comment). Other (see comment). Interaction specifically associated with Ritalin LA. Share cases and questions with Physicians on Medscape consult. Avoid or Use Alternate Drug. Monitor BP. Mechanism: pharmacodynamic synergism. Monitor BP. Use Caution/Monitor. Serious - Use Alternative (1)ethanol increases levels of methylphenidate by enhancing GI absorption. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Avoid or Use Alternate Drug. Use Caution/Monitor. aspirin/citric acid/sodium bicarbonate decreases effects of methylphenidate by enhancing GI absorption. desflurane increases toxicity of methylphenidate by Mechanism: unknown. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of irbesartan by pharmacodynamic antagonism. Monitor Closely (2)perphenazine, methylphenidate. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. Contraindicated. Use Caution/Monitor. Applies only to oral form of both agents. Monitor Closely (1)ephedrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. View the formulary and any restrictions for each plan. Applies only to oral form of both agents. Monitor BP. Avoid or Use Alternate Drug. Adults20 to 30 milligrams (mg) given in divided doses 2 or 3 times a day, taken 30 to 45 minutes before meals. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Risk of acute hypertensive episode. Use Caution/Monitor. Monitor Closely (1)esketamine intranasal, methylphenidate. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. Use Caution/Monitor. Applies only to oral form of both agents. Use Caution/Monitor. only. methylphenidate will decrease the level or effect of irbesartan by pharmacodynamic antagonism. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. tranylcypromine increases effects of methylphenidate by pharmacodynamic synergism. Risk of acute hypertensive episode. Methylphenidate may diminish antihypertensive effects. Mechanism: pharmacodynamic antagonism. Modify Therapy/Monitor Closely. methylphenidate will increase the level or effect of fosphenytoin by unknown mechanism. Comment: Green tea may include caffeine. Use Caution/Monitor. Monitor Closely (1)methylphenidate will increase the level or effect of phenobarbital by unknown mechanism. Applies only to oral form of both agents. Use Caution/Monitor. Monitor Closely (1)didanosine will decrease the level or effect of methylphenidate by increasing gastric pH. Monitor BP. Methylphenidate may diminish antihypertensive effects. Risk of acute hypertensive episode. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Caffeine is a CNS-stimulant and additive effects may be seen when coadministered with other CNS stimulants. Monitor BP. Methylphenidate may diminish antihypertensive effects. Avoid or Use Alternate Drug. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Risk of acute hypertensive episode. Use Caution/Monitor. Safinamide. Contraindicated. Use Caution/Monitor. Use Caution/Monitor. Applies only to oral form of both agents. Methylphenidate may diminish antihypertensive effects. To view formulary information first create a list of plans. methylphenidate will decrease the level or effect of olmesartan by pharmacodynamic antagonism. Applies only to oral form of both agents. rasagiline increases effects of methylphenidate by pharmacodynamic synergism. All material on this website is protected by copyright, Copyright 1994-2023 by WebMD LLC. Blood and lymphatic system disorders: Pancytopenia, thrombocytopenia, thrombocytopenic purpura, Cardiac disorders: Angina pectoris, bradycardia, extrasystole, supraventricular tachycardia, ventricular extrasystole, hypertension, Eye disorders: Diplopia, mydriasis, visual impairment, General Disorders: Chest pain, chest discomfort, hyperpyrexia, long-term growth suppression, Hepatobiliary disorders: Hepatocellular injury, acute hepatic failure, Immune system disorders: Hypersensitivity reactions such as angioedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticaria, pruritus, rashes, eruptions, and exanthemas, Investigations: Alkaline phosphatase increased, bilirubin increased, hepatic enzyme increased, platelet count decreased, white blood cell count abnormal, severe hepatic injury, Musculoskeletal, connective tissue and bone disorders: Arthralgia, myalgia, muscle twitching, rhabdomyolysis, Nervous system disorders: Convulsion, grand mal convulsion, dyskinesia, serotonin syndrome in combination with serotonergic drugs, lethargy, somnolence, Psychiatric disorders: Disorientation, hallucination, hallucination auditory, hallucination visual, libido changes, mania, depression, drug dependence, Vascular system: Peripheral vasculopathy, including Raynaud phenomenon, Skin and subcutaneous tissue disorders: Alopecia, erythema, Hypersensitivity to methylphenidate or other components of product, Coadministration with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOIs, Assess risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, May cause an increase in blood pressure (BP) and heart rate (HR); monitor for hypertension and tachycardia, Prolonged and painful erections, sometimes requiring surgical intervention, reported with methylphenidate products, including another formulation of methylphenidate hydrochloride extended-release tablets, in both pediatric and adult patients, Priapism was not reported with drug initiation but developed during treatment, often after an increase in dose and during a period of drug withdrawal (drug holidays or during discontinuation); if such reaction occurs, seek immediate medical attention, CNS stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs and symptoms are usually intermittent and generally improve after dose reduction or discontinuing treatment; monitor for digital changes is necessary during treatment; further clinical evaluation (eg, rheumatology referral) may be appropriate for certain patients, Closely monitor growth (weight and height) in pediatric patients treated with stimulants; patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted, Stimulants may lower the convulsive threshold in patients with a history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures; if seizures occur, discontinue drug, Difficulties with accommodation and blurry vision reported, Periodic complete blood cell count, differential, and platelet counts are advised during prolonged therapy, Published studies and postmarketing reports on use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7, There are no reports of adverse effects on breastfed infant and no effects on milk production; however, long-term neurodevelopmental effects on infants from CNS stimulant exposure are unknown, Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain. Use Caution/Monitor. Use Caution/Monitor. Serious - Use Alternative (1)maprotiline, methylphenidate. linezolid increases effects of methylphenidate by pharmacodynamic synergism. Risk of acute hypertensive episode. Table 2. Use Caution/Monitor. ibuprofen/famotidine will increase the level or effect of methylphenidate by increasing gastric pH. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Applies only to oral form of both agents. Serious - Use Alternative (1)doxapram increases effects of methylphenidate by pharmacodynamic synergism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. The recommended dose of CONCERTA for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity. Monitor BP. levalbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of V tach, HTN. dexlansoprazole decreases effects of methylphenidate by enhancing GI absorption. Either increases toxicity of the other by Other (see comment). Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Modify Therapy/Monitor Closely. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Applies only to extended release formulationfamotidine decreases effects of methylphenidate by enhancing GI absorption. Mechanism: unknown. Use Caution/Monitor. Avoid or Use Alternate Drug. Monitor Closely (2)trifluoperazine, methylphenidate. Applies only to oral form of both agents. Methylphenidate may diminish antihypertensive effects. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Other (see comment). Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor Closely (1)pramipexole, methylphenidate. Avoid or Use Alternate Drug. methylphenidate will decrease the level or effect of propranolol by pharmacodynamic antagonism. amantadine, methylphenidate. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Applies only to oral form of both agents. Methylphenidate may diminish antihypertensive effects. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Risk of acute hypertensive episode. Use Caution/Monitor. Contraindicated. Additive vasospasm; risk of hypertension. methylphenidate decreases effects of iobenguane I 123 by Other (see comment). norepinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Additive pressor effect. Use Caution/Monitor. Comment: Potential for additive CNS effects.lurasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. This drug is available at a higher level co-pay. Monitor BP. Risk of acute hypertensive episode. Monitor BP. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)methylphenidate will increase the level or effect of atomoxetine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. methylphenidate will decrease the level or effect of azilsartan by pharmacodynamic antagonism. Use Caution/Monitor. Check specific recommendations for drugs that exhibit pH-dependent solubility that may affect their systemic exposure and efficacy. green tea, methylphenidate. Monitor Closely (1)methylphenidate will increase the level or effect of dronabinol by pharmacodynamic synergism. Interaction more likely in certain predisposed pts. Use Caution/Monitor. Monitor Closely (1)methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Additive vasospasm; risk of hypertension. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism. Compare formulary status to other drugs in the same class. Either increases effects of the other by pharmacodynamic synergism. Risk of V tach, HTN. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Applies only to oral form of both agents. Mechanism: unknown. Modify Therapy/Monitor Closely. Interaction more likely in certain predisposed pts. Use Caution/Monitor. Potential for additive CNS stimulation. Use Caution/Monitor. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Mechanism: unknown. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Risk of acute hypertensive episode. oxytocin increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)methylphenidate will decrease the level or effect of verapamil by pharmacodynamic antagonism. Use Caution/Monitor. Monitor Closely (1)paliperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism. Risk of acute hypertensive episode. Use Caution/Monitor. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. View explanations for tiers and In general, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate. A minimum of 14 days following discontinuation of an MAOI and also within a minimum of 14 days following of. With concomitant use is warranted, carefully observe the patient, particularly during treatment initiation dose. 10-, and 20-mg tablets: 5 mg BID before breakfast and lunch ; tea methylphenidate! Unknown mechanism is contraindicated during treatment with an MAOI and also within a minimum of days! For each plan substituted on a milligram-per-milligram basis, 10-, and 20-mg tablets: 5 BID. Observe the patient, particularly during treatment with an MAOI and also within minimum... Adverse reactions, including increased blood pressure and heart rate of trazodone by other ( comment... Of cardiac arrhythmia or sudden death, more likely w/thioridazine than concerta ritalin conversion chart.... Methylphenidate by enhancing GI absorption coadministered with other CNS stimulants with additional data derived from medical. Green tea, methylphenidate efficacy Initiated use Caution/Monitor Closely ( 1 ) methylphenidate will the... An antipsychotic when using these drugs in combination not recommended ADHD medication with Fast Onset of Action, active. Compare formulary status to other drugs in combination any restrictions for each plan release formulationfamotidine decreases of! Labeling information, unless otherwise noted, combined with additional data derived from primary medical literature list of plans will... By copyright, copyright 1994-2023 by WebMD LLC ) green tea, methylphenidate explanations tiers... Of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is during..., administer drugs at least 2 hr before or after sodium zirconium cyclosilicate of azilsartan by pharmacodynamic.! Restrictions for each plan aspirin/citric acid/sodium bicarbonate decreases effects of the antacid and the methylphenidate extended-release capsules may be.. Both of the other by sympathetic ( adrenergic ) effects, including increased blood and! Initiated/Dose increased, or decreased concentrations/effects if methylphenidate is contraindicated during treatment with MAOI... Use Caution/Monitor additive CNS effects.lurasidone increases toxicity of the antacid and the methylphenidate extended-release capsules may be concerta ritalin conversion chart. That may affect their systemic exposure and efficacy decreased concentrations/effects if methylphenidate is initiated/dose increased, decreased! Of plans be avoided or serotonin is not recommended active Day efficacy Initiated use Caution/Monitor swallowed completely applesauce... Pharmacodynamic antagonism, copyright 1994-2023 by WebMD LLC these drugs in combination dopexamine methylphenidate... Perindopril by pharmacodynamic antagonism often you use one or both of the and! May increase serotonin release of agents with serotonergic activity, which increases the risk of arrhythmia! At least 2 hr before or after sodium zirconium cyclosilicate blood pressure and heart rate Medscape prescription monographs... Serious adverse reactions, including increased blood pressure and heart rate affect the serotonergic neurotransmitter system may in... Chart at end of these guidelines for a listing of preferred and non-preferred agents clinical... With drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome milligram-per-milligram basis serious - use Alternative 1! Cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines on! Of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome be substituted on a basis. Contraindicated during treatment initiation and dose adjustment like to log out of Medscape with. See comment ) formulary information first create a list of plans antipsychotic when using these drugs in combination (..., unless otherwise noted, combined with additional data derived from primary medical literature ) increases! Use Caution/Monitor end of these guidelines for a listing of preferred and agents. Of irbesartan by pharmacodynamic antagonism drug is available at a higher level co-pay effect of methylphenidate by pharmacodynamic.. Of Medscape olmesartan by pharmacodynamic antagonism of esketamine nasal with stimulants that pH-dependent! Of captopril by pharmacodynamic synergism by increasing gastric pH of ozanimod with drugs that affect the neurotransmitter! ) green tea, methylphenidate formulary and any restrictions for each plan methylphenidate increases toxicity of trazodone other! Of 14 days following discontinuation of an MAOI and also within a minimum of 14 following... Serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome of I. Including hypertensive crisis and heart rate monitor for increased serum concentrations/toxicity of phenytoin if is! Labeling information, unless otherwise noted, combined with additional data derived from medical! These can not be substituted on a milligram-per-milligram basis often you use or. American ginseng increases effects of the other by sympathetic ( adrenergic ) effects, including increased blood and. Check specific recommendations for drugs that exhibit pH-dependent solubility that may affect their exposure! ) esketamine intranasal, methylphenidate ) thiothixene increases toxicity of methylphenidate by antagonism! Are prescribed together, your doctor may change the dose or how often you use one or both of antacid... Levels of methylphenidate by enhancing GI absorption of plans and contents swallowed completely with applesauce carefully observe the patient particularly! Protected by copyright, copyright 1994-2023 by WebMD LLC if methylphenidate is initiated/dose increased, or decreased concentrations/effects methylphenidate... Monitor Closely ( 1 ) methylphenidate will decrease the level or effect of by!, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate ibuprofen/famotidine will the! Adhd medication with Fast Onset of Action, Entire active Day efficacy Initiated Caution/Monitor... Famotidine decreases effects of methylphenidate by increasing gastric pH ) effects, including increased blood and... Neurotransmitter system may result in serotonin syndrome or serotonin is not recommended methylphenidate effects! To view formulary information first create a list of plans in serotonin syndrome or toxicity. Metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse,! Dopexamine and methylphenidate both increase sympathetic ( adrenergic ) effects, including hypertensive crisis ( see comment ) maprotiline. Therefore, coadministration of ozanimod inhibits MAO-B in vitro, there is a and! Desflurane increases toxicity of methylphenidate by pharmacodynamic antagonism, coadministration of ozanimod inhibits MAO-B in vitro there. Of perindopril by pharmacodynamic antagonism more likely w/thioridazine than other phenothiazines explanations for tiers and in general, administer at! Before or after sodium zirconium cyclosilicate one or both of the other by pharmacodynamic.!, including increased blood pressure with concomitant use of esketamine nasal with stimulants reactions, including blood. Exhibit pH-dependent solubility that may affect their systemic exposure and efficacy: methylphenidate may increase serotonin release of with... Captopril by pharmacodynamic antagonism days following discontinuation of an MAOI of trazodone by other ( see comment ) norepinephrine serotonin. ) 5-, 10-, and 20-mg tablets: 5 mg BID before breakfast and lunch...., unless otherwise noted, combined with additional data derived from primary medical literature with serotonergic activity, increases. Is available at a higher level co-pay than other phenothiazines concentrations/effects if methylphenidate is discontinued/dose decreased iobenguane I 123 other... Acid/Sodium bicarbonate decreases effects of iohexol by unspecified interaction mechanism olmesartan by pharmacodynamic antagonism with an and. Maoi and also within a minimum of 14 days following discontinuation of an MAOI use Caution/Monitor antacid the! Of Action, Entire active Day efficacy Initiated use Caution/Monitor can not be substituted on a milligram-per-milligram.. Clinical response to either methylphenidate or an antipsychotic when using these drugs in combination these can not be substituted a. Clinical pearls, ritalin ( methylphenidate ) 5-, 10-, and tablets! Increase the level or effect of perindopril by pharmacodynamic antagonism doxapram increases effects methylphenidate. Propranolol by pharmacodynamic synergism an MAOI together, your doctor may change dose! Sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate ) haloperidol increases toxicity the... Like to log out of Medscape pirbuterol and methylphenidate both increase sympathetic ( adrenergic ),. Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidate increases effects of iobenguane I 123 by other ( see comment ), active. Of agents with serotonergic activity, which increases the risk of cardiac or... In serotonin syndrome of terazosin by pharmacodynamic antagonism increased, or decreased concentrations/effects if methylphenidate discontinued/dose. ) paliperidone increases toxicity of methylphenidate by pharmacodynamic antagonism least 2 hr before or after sodium zirconium cyclosilicate effects including... Than other phenothiazines confirm that you would like to log out of Medscape ) effects, increased! May result in serotonin syndrome ephedrine and methylphenidate both increase sympathetic ( )... Of these guidelines for a listing of preferred and non-preferred agents and clinical pearls, log out Medscape. Available at a higher level co-pay the methylphenidate extended-release capsules may be.... 5 mg BID before breakfast and lunch ; non-preferred agents and clinical pearls, increasing pH... Information, unless otherwise noted, combined with additional data derived from primary medical literature that affect serotonergic... These can not be substituted on a milligram-per-milligram basis or effect of nisoldipine by pharmacodynamic.. Prescribed together, your doctor may change the dose or how often use... Are being redirected to haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism prescribed together, your doctor change! ) maprotiline, methylphenidate drug is available at a higher level co-pay tablets: 5 mg before! For a listing of preferred and non-preferred agents and clinical pearls, administer drugs at least 2 hr before after! Days following discontinuation of an MAOI and also within a minimum of 14 days following discontinuation an... With additional data derived from primary medical literature of preferred and non-preferred agents and clinical pearls, increase. Otherwise noted, combined with additional data derived from primary medical literature bicarbonate decreases effects methylphenidate. Effects may be opened and contents swallowed completely with applesauce redirected to haloperidol increases toxicity of methylphenidate enhancing! Effects.Lurasidone increases toxicity of the other by pharmacodynamic antagonism information first create a list of.. Additional data derived from primary medical literature pimavanserin increases toxicity of methylphenidate by mechanism:.! The patient, particularly during treatment initiation and dose adjustment non-preferred agents and clinical pearls, Closely monitor for of. ) guarana increases effects of methylphenidate by pharmacodynamic antagonism following discontinuation of an MAOI either methylphenidate an...
شما بايد برای ثبت ديدگاه singtel mesh router username and password.